CRISPR-based assays for rapid detection of SARS-CoV-2.
COVID-19
CRISPR diagnostics
Diagnostic advancements
Molecular testing
SARS-CoV-2
Journal
Methods (San Diego, Calif.)
ISSN: 1095-9130
Titre abrégé: Methods
Pays: United States
ID NLM: 9426302
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
received:
28
07
2020
revised:
16
09
2020
accepted:
06
10
2020
pubmed:
13
10
2020
medline:
22
6
2022
entrez:
12
10
2020
Statut:
ppublish
Résumé
COVID-19 pandemic posed an unprecedented threat to global public health and economies. There is no effective treatment of the disease, hence, scaling up testing for rapid diagnosis of SARS-CoV-2 infected patients and quarantine them from healthy individuals is one the best strategies to curb the pandemic. Establishing globally accepted easy-to-access diagnostic tests is extremely important to understanding the epidemiology of the present pandemic. While nucleic acid based tests are considered to be more sensitive with respect to serological tests but present gold standard qRT-PCR-based assays possess limitations such as low sample throughput, requirement for sophisticated reagents and instrumentation. To overcome these shortcomings, recent efforts of incorporating LAMP-based isothermal detection, and minimizing the number of reagents required are on rise. CRISPR based novel techniques, when merge with isothermal and allied technologies, promises to provide sensitive and rapid detection of SARS-CoV-2 nucleic acids. Here, we discuss and present compilation of state-of-the-art detection techniques for COVID-19 using CRISPR technology which has tremendous potential to transform diagnostics and epidemiology.
Identifiants
pubmed: 33045362
pii: S1046-2023(20)30217-6
doi: 10.1016/j.ymeth.2020.10.003
pmc: PMC7546951
pii:
doi:
Substances chimiques
RNA, Viral
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
594-603Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Références
Arch Virol. 2011 Apr;156(4):671-80
pubmed: 21221674
CRISPR J. 2020 Dec;3(6):487-502
pubmed: 33346711
J Clin Microbiol. 2014 Jun;52(6):1883-92
pubmed: 24648561
Clin Chem. 2005 Oct;51(10):1885-8
pubmed: 16189379
Science. 2018 Apr 27;360(6387):381-382
pubmed: 29700254
Int J Infect Dis. 2020 May;94:44-48
pubmed: 32171952
J Clin Microbiol. 2008 Mar;46(3):837-41
pubmed: 18160451
J Virol Methods. 2004 Jul;119(1):17-23
pubmed: 15109816
Science. 2017 Apr 28;356(6336):438-442
pubmed: 28408723
Clin Vaccine Immunol. 2011 Dec;18(12):2090-4
pubmed: 21994352
Sci Rep. 2019 Mar 14;9(1):4494
pubmed: 30872672
Science. 2018 Apr 27;360(6387):444-448
pubmed: 29700266
J Travel Med. 2020 Mar 13;27(2):
pubmed: 32052841
Arch Virol. 2017 Jun;162(6):1617-1623
pubmed: 28220326
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
Cell Discov. 2020 May 19;6:34
pubmed: 32435508
Nat Commun. 2020 Sep 18;11(1):4711
pubmed: 32948757
Science. 2018 Apr 27;360(6387):436-439
pubmed: 29449511
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
Nature. 2020 Jun;582(7811):277-282
pubmed: 32349121
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Nat Commun. 2020 Sep 30;11(1):4906
pubmed: 32999292
Nat Biotechnol. 2020 Jul;38(7):870-874
pubmed: 32300245
Science. 2018 Apr 27;360(6387):439-444
pubmed: 29449508
Science. 2018 Aug 31;361(6405):866-869
pubmed: 30166482
Clin Infect Dis. 2017 Sep 15;65(6):1026-1032
pubmed: 28520858
J Autoimmun. 2020 May;109:102433
pubmed: 32113704
J Virol Methods. 2011 Dec;178(1-2):75-81
pubmed: 21889540
Diagn Microbiol Infect Dis. 2018 Jul;91(3):245-247
pubmed: 29550057
J Clin Microbiol. 2004 May;42(5):1956-61
pubmed: 15131154